PharmiWeb.com - Global Pharma News & Resources
27-Jun-2023

Antinuclear Antibody Test Market Size (USD 5.0 billion by 2031) Pioneering Growth to Fulfill Healthcare Requirements

Antinuclear antibodies can be found in a person’s blood serum using an antinuclear antibody test. Antinuclear antibody (ANA) testing is used to identify autoimmune illnesses that damage the tissues and organs of the body. These tests check the blood serum for antinuclear antibodies. Antibodies made by the human immune system defend the body from invaders such as viruses and bacteria. Antinuclear antibodies, on the other hand, attack the patient’s own healthy cells and result in autoimmune illness. Systemic lupus erythematosus, rheumatoid arthritis, scleroderma, and Sjogren’s syndrome are just a few of the major health problems that can be brought on by autoimmune illnesses.

Allied Market Research has just completed and published a study report with the title Antinuclear Antibody Test Market Size was Valued at USD 1.3 billion in 2021, and is Projected to Garner USD 5.0 billion by 2031 registering a CAGR of 15.0% from 2022 to 2031.

The report provides an extensive analysis of changing market dynamics, major segments, value chain, competitive scenario, and regional landscape. This research offers a valuable guidance to leading players, investors, shareholders, and startups in devising strategies for sustainable growth and gaining competitive edge in the market.

Covid-19 scenario-

  • The outbreak of the pandemic impacted the global antinuclear antibody test market negatively since the majority of people were getting these tests to monitor their health and evaluate their risk for autoimmune illnesses during the crisis.
  • Increasing frequency of chronic diseases and rising elderly population are the major causes behind the market expansion.

Get Sample PDF Report with Graphs and Figures Here: https://www.alliedmarketresearch.com/request-sample/4259

𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐑𝐞𝐜𝐞𝐧𝐭 𝐓𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐭𝐡𝐞 Antinuclear Antibody Test Market?

Increasing prevalence of autoimmune diseases among people drives the growth of the global antinuclear antibody test market. Moreover, the fact that antinuclear antibody tests are becoming more and more popular as a way to diagnose autoimmune diseases such as rheumatoid arthritis, Systemic Lupus Erythematosus, Sjogren’s Syndrome, and others has supplemented the growth even more. Moreover, growing government healthcare insurance and rising awareness about autoimmune disorders are expected to create lucrative opportunities in the industry.

𝐓𝐨𝐩 Antinuclear Antibody Test 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬

  • Bio-Rad Laboratories, Inc.
  • Erba Diagnostics
  • Thermo Fisher Scientific
  • Antibodies Incorporated
  • Trinity Biotech Plc.
  • Immuno Concepts NA Ltd.
  • ZEUS Scientific, Inc.
  • Inova Diagnostics, Inc.
  • EUROIMMUN Medizinische Labordiagnostika AG.

Antinuclear Antibody Test 𝐌𝐚𝐫𝐤𝐞𝐭 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐜𝐚𝐧 𝐛𝐞 𝐝𝐨𝐧𝐞 𝐛𝐚𝐬𝐞𝐝 𝐨𝐧 𝐬𝐞𝐯𝐞𝐫𝐚𝐥 𝐟𝐚𝐜𝐭𝐨𝐫𝐬, 𝐢𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠:

By product, the reagents & assay kits segment contributed to around three-fifths of the global antinuclear antibody test market share in 2021, and is expected to lead the trail by 2031. The same segment would also garner the fastest CAGR of 15.53% during the forecast period. Rise in the use of these kits for various research and development purposes for a better understanding of various types of diseases drives the segment growth.

Based on technique, the ELISA segment generated around two-fifths of the global antinuclear antibody test market revenue in 2021, and is expected to lead the trail by 2031. The same segment would also portray the fastest CAGR of 15.67% from 2022-2031. This is because the ELISA test is quick and produces data more quickly than other testing methods.

Based on application, the rheumatoid arthritis segment held more than two-thirds of the global antinuclear antibody test market revenue in 2021. The same segment would also manifest the fastest CAGR of 15.46% from 2022 to 2031. This is attributed to the growing elderly population and increase in cases of rheumatoid arthritis across the world.

By end-use, the hospitals segment contributed to around two-fifths of the global antinuclear antibody test market share in 2021, and is expected to retain its dominance by 2031. Increase in patient satisfaction, outpatient services, and enhanced home care facilities offered by hospitals fuel the growth of the segment. The physician office laboratories segment, on the other hand, is expected to exhibit the fastest CAGR of 15.97% from 2022 to 2031.

Based on region, North America held the major share in 2021, generating nearly two-fifths of the global antinuclear antibody test market. Increasing prevalence of autoimmune illnesses propels the market growth. The Asia-Pacific region, simultaneously, would cite the fastest CAGR of 17.1% throughout the forecast period. With the growing population on board, the likelihood of developing autoimmune diseases has increased significantly. The other provinces studied through the report include Europe and LAMEA.

Purchase the Report: https://www.alliedmarketresearch.com/purchase-enquiry/4259

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antinuclear antibody test market analysis from 2021 to 2031 to identify the prevailing antinuclear antibody test market opportunities.
  • The market research is offered along with information related to antinuclear antibody test market forecast, key drivers, restraints, and opportunities.
  • Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the antinuclear antibody test market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global antinuclear antibody test market trends, key players, market segments, application areas, and market growth strategies.

Our Market Research Solution Provides You Answer to Below Mentioned Question:

  • Which are the driving factors responsible for the growth of market?
  • Which are the roadblock factors of this market?
  • What are the new opportunities, by which market will grow in coming years?
  • What are the trends of this market?
  • Which are main factors responsible for new product launch?
  • How big is the global & regional market in terms of revenue, sales and production?
  • How far will the market grow in forecast period in terms of revenue, sales and production?
  • Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
  • How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
  • Which region has more opportunities?

By Region Outlook 

  • North America
    (U.S., Canada, Mexico)
  •  Europe
    (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific
    (Japan, China, India, Rest of Asia-Pacific)
  • LAMEA
    (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

 

Editor Details

  • Company:
    • The Wire Times
Last Updated: 27-Jun-2023